A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To confirm the safety and feasibility of canakinumab and spartalizumab (PDR-001)
administered using a standard dose / schedule in the neo-adjuvant setting in renal cell
carcinoma
Secondary Objectives:
- To assess the immune response to combination canakinumab and spartalizumab
- To assess anti-tumor activity as measured by pathologic downstaging